OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
0928$0.0857

King International Investment Ltd

Healthcare Facilities & ServicesVerified

King International Investment Ltd exhibits a capital structure with a market price of $0.079 and a market cap of $146.18 million, indicating a relatively small capitalization. The company's price-to-book ratio of 0.66 suggests that the market values the company at a discount to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible assets are being capitalized. The enterprise value to revenue ratio of 3.64 implies a moderate valuation relative to its revenue, but the negative EV/EBITDA of -3.37 highlights a lack of profitability and potential operational inefficiencies. Profitability metrics are concerning, with a return on equity of -21.31% and a return on assets of -16.57%, both significantly below industry norms. The company reported a net loss of $47.45 million and an operating loss of $44.11 million, indicating a failure to generate positive returns from its operations. Gross profit of $12.73 million is insufficient to cover operating expenses, which is a red flag for investors. The company's revenue is split between two segments: Healthcare Products and Services, and Sales of Liquor. While the financial data does not provide a breakdown of revenue by segment, the company's exposure to the liquor business may introduce volatility due to market demand and regulatory changes. The geographic exposure is not disclosed, but the company is listed in Hong Kong, suggesting potential exposure to regional economic conditions. Growth trajectory is negative, with the company reporting declining revenues and increasing losses. The outlook for the current fiscal year is not optimistic, and there is no indication of a turnaround in the next fiscal year. The company's free cash flow is negative at -$46.6 million, indicating a lack of liquidity and the need for external financing. Risk factors include a medium liquidity risk, as the company has a negative net cash position after subtracting total debt. The dilution risk is low, but the company's negative operating cash flow of -$322,000 and the absence of positive cash generation from operations pose a threat to its financial stability. No dilution sources are identified in the provided data, and there is no near-term pressure for dilution. Recent events include the latest financial filing, which discloses the company's poor performance. No significant events or transcripts are provided that would indicate a strategic shift or operational improvement.

30-day price · 0928+0.00 (+1.3%)
Low$0.07High$0.10Close$0.08As of22 May, 00:00 UTC
Profile
CompanyKing International Investment Ltd
Ticker0928.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. King International Investment Ltd operates as an investment holding company primarily engaged in health products and services, including genetic testing, health data analysis, and health product trading, as well as the sale of Maotai-flavor liquor and other liquors.

Classification. King International Investment Ltd is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

King International Investment Ltd exhibits a capital structure with a market price of $0.079 and a market cap of $146.18 million, indicating a relatively small capitalization. The company's price-to-book ratio of 0.66 suggests that the market values the company at a discount to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible assets are being capitalized. The enterprise value to revenue ratio of 3.64 implies a moderate valuation relative to its revenue, but the negative EV/EBITDA of -3.37 highlights a lack of profitability and potential operational inefficiencies. Profitability metrics are concerning, with a return on equity of -21.31% and a return on assets of -16.57%, both significantly below industry norms. The company reported a net loss of $47.45 million and an operating loss of $44.11 million, indicating a failure to generate positive returns from its operations. Gross profit of $12.73 million is insufficient to cover operating expenses, which is a red flag for investors. The company's revenue is split between two segments: Healthcare Products and Services, and Sales of Liquor. While the financial data does not provide a breakdown of revenue by segment, the company's exposure to the liquor business may introduce volatility due to market demand and regulatory changes. The geographic exposure is not disclosed, but the company is listed in Hong Kong, suggesting potential exposure to regional economic conditions. Growth trajectory is negative, with the company reporting declining revenues and increasing losses. The outlook for the current fiscal year is not optimistic, and there is no indication of a turnaround in the next fiscal year. The company's free cash flow is negative at -$46.6 million, indicating a lack of liquidity and the need for external financing. Risk factors include a medium liquidity risk, as the company has a negative net cash position after subtracting total debt. The dilution risk is low, but the company's negative operating cash flow of -$322,000 and the absence of positive cash generation from operations pose a threat to its financial stability. No dilution sources are identified in the provided data, and there is no near-term pressure for dilution. Recent events include the latest financial filing, which discloses the company's poor performance. No significant events or transcripts are provided that would indicate a strategic shift or operational improvement.
Key takeaways
  • King International Investment Ltd is operating at a significant loss, with a return on equity of -21.31% and a return on assets of -16.57%.
  • The company's market cap of $146.18 million is significantly lower than its book value, as indicated by a price-to-book ratio of 0.66.
  • The enterprise value to revenue ratio of 3.64 suggests a moderate valuation, but the negative EV/EBITDA of -3.37 highlights operational inefficiencies.
  • The company's liquidity is at risk, with a negative net cash position and a free cash flow of -$46.6 million.
  • The company's growth trajectory is negative, with no indication of a turnaround in the near future.
  • The company's risk profile includes medium liquidity risk and low dilution risk, but the lack of positive cash flow is a concern.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyHKD
Revenue$40.8M
Gross profit$12.7M
Operating income-$44.1M
Net income-$47.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$322.0k
CapEx
Free cash flow-$46.6M
Total assets$286.4M
Total liabilities$63.7M
Total equity$222.6M
Cash & equivalents
Long-term debt$2.4M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$0.08
Market cap$146.2M
Enterprise value$148.6M
P/E
Reported non-GAAP P/E
EV/Revenue3.6
EV/Op income
EV/OCF
P/B0.7
P/Tangible book0.7
Tangible book$222.6M
Net cash-$2.4M
Current ratio4.6
Debt/Equity0.0
ROA-16.6%
ROE-21.3%
Cash conversion1.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric0928Activity
Op margin-108.2%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin-116.4%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin31.2%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue4.2% medp25 3.8% · p75 4.2%
Debt / equity1.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 09:09 UTC#e8901aef
Market quoteclose HKD 0.08 · shares 1.85B diluted
no public URL
2026-05-04 09:09 UTC#9f92bcc7
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 09:10 UTCJob: b5218924